PRIVIGEN AU normal immunoglobulin (human) 20g (100g/L, 10%) solution for intravenous infusion Australia - English - Department of Health (Therapeutic Goods Administration)

privigen au normal immunoglobulin (human) 20g (100g/l, 10%) solution for intravenous infusion

csl behring australia pty ltd - normal immunoglobulin, quantity: 20 g - injection, solution - excipient ingredients: water for injections; proline - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).

PRIVIGEN AU normal immunoglobulin (human) 10g (100g/L, 10%) solution for intravenous infusion Australia - English - Department of Health (Therapeutic Goods Administration)

privigen au normal immunoglobulin (human) 10g (100g/l, 10%) solution for intravenous infusion

csl behring australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: proline; water for injections - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).

PRIVIGEN AU normal immunoglobulin (human) 5g (100g/L, 10%) solution for intravenous infusion Australia - English - Department of Health (Therapeutic Goods Administration)

privigen au normal immunoglobulin (human) 5g (100g/l, 10%) solution for intravenous infusion

csl behring australia pty ltd - normal immunoglobulin, quantity: 5 g - injection, solution - excipient ingredients: proline; water for injections - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).

CSL Malaysia Intragam P Normal Immunoglobulin (Human) 6% w/v (60 g/L) Solution for Intravenous Use Australia - English - Department of Health (Therapeutic Goods Administration)

csl malaysia intragam p normal immunoglobulin (human) 6% w/v (60 g/l) solution for intravenous use

csl behring australia pty ltd - normal immunoglobulin, quantity: 3 g - injection, solution - excipient ingredients: human immunoglobulin a; maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency (pid); * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with with recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease; * guillain-barre syndrome (gbs).

INTRAGAM P immunoglobulin-normal (human) 30g/500mL for intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

intragam p immunoglobulin-normal (human) 30g/500ml for intravenous use injection vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 mg/ml - injection, solution - excipient ingredients: maltose; human immunoglobulin a; water for injections - intragam p is indicated in replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. indications as at 21 july 2000: replacement igg therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; kawasaki disease. indications as at 25 february 2003: for replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; congenital acquired immune deficiency syndrome with recurrent infections. for immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogeneic bone marrow transplantation; kawasaki disease, and; guillain-barre syndrome (gbs).

XIIDRA lifitegrast 50 mg/mL eye drops single-use ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

xiidra lifitegrast 50 mg/ml eye drops single-use ampoules

bausch & lomb australia pty ltd - lifitegrast, quantity: 50 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; sodium hydroxide; sodium thiosulfate pentahydrate; water for injections; dibasic sodium phosphate - xiidra is indicated for the treatment of moderate to severe dry eye disease in adults for whom prior use of artificial tears has not been sufficient.

INTRATECT 20g in 200 mL human normal immunoglobulin solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

intratect 20g in 200 ml human normal immunoglobulin solution for intravenous infusion vial

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.

INTRATECT 10g in 100 mL human normal immunoglobulin solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

intratect 10g in 100 ml human normal immunoglobulin solution for intravenous infusion vial

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.

INTRATECT 5g in 50 mL human normal immunoglobulin solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

intratect 5g in 50 ml human normal immunoglobulin solution for intravenous infusion vial

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.

INTRATECT 1g in 10 mL human normal immunoglobulin solution for intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

intratect 1g in 10 ml human normal immunoglobulin solution for intravenous infusion vial

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.